I akut tibiafraktur studier udviklede 4, 4% af patienterne behandlet med InductOs antistoffer sammenlignet med 0, 6% i kontrolgruppen.
In acute tibia fracture studies, 4.4% of patients receiving InductOs developed antibodies vs 0.6% in the control group.